Drug Safety

, Volume 28, Issue 12, pp 1075–1083 | Cite as

Sex Differences in Antiretroviral Therapy-Associated Intolerance and Adverse Events

Current Opinion

Abstract

Although women account for a substantial proportion of the global population infected with HIV, most clinical trials evaluating the safety and efficacy of specific antiretroviral therapy regimens have been preformed in predominantly male cohorts. Our knowledge of the sex differences associated with responses to these treatments is therefore limited. Potentially sex-specific influences, such as endogenous or exogenous hormones, could impact antiretroviral tolerance. Women also have different pharmacokinetic profiles for selected antiretrovirals compared with men. These factors could influence how women respond and react to antiretrovirals. Several observational studies have described a higher frequency of antiretroviral-related adverse effects among women compared with men. Women appear to be at an especially high risk for lactic acidosis, nevirapine-associated rashes and hepatotoxicity, and fat redistribution after highly active antiretroviral therapy exposure. Although a statistical association between antiretroviral toxicity and pregnancy has not been described, pregnancy may provide an additional influence on the toxicity of several antiretrovirals or antiretroviral combinations. Potential tolerability should be an important component in discussions of antiretroviral options among women.

References

  1. 1.
    UNAIDS. AIDS epidemic update 2002 [online]. Available from URL: http://www.unaids.org [Accessed 2004 Sep 24]Google Scholar
  2. 2.
    Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 2003; 11: 55–9PubMedGoogle Scholar
  3. 3.
    Fletcher C. Gender differences in antiretroviral therapy pharmacokinetics and pharmacodynamics [online]. Available from URL: http://www.retroconference.org/2004/pages/webcast.htm [Accessed 2004 Sep 24]
  4. 4.
    Flexner CW. Factors associated with pharmacokinetic variability in HIV-infected patient. MedOptions 2004 i, LLCGoogle Scholar
  5. 5.
    Hitti J, Rosenkranz S, Cohn S, et al. Sex and weight as covariates in the pharmacokinetics of efavirenz and nelfinavir (abstract no. 604) [online]. Available from URL: http://www.retroconference.org/2004/ [Accessed 2004 Sep 24]
  6. 6.
    Brundage RC, Acosta EP, Haubrich R, et al. Quantitation of sex differences and drug interactions: pharmacologic studies of saquinavir in ACTG 359 (abstract no. 779-W) [online]. Available from URL: http://www.retroconference.org/2002/ [Accessed 2004 Sep 24]
  7. 7.
    Burger D, la Porte C, vander Ende M, et al. Gender-related differences in efavirenz pharmakokinetics [abstract no. 15]. Program and abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy; 2003 Mar 27-29; CannesGoogle Scholar
  8. 8.
    Ribaudo H, Clifford D, Gulick R, et al. Relationships between efavirenz pharmacokinetics, side effects, discontinuation, virologic response, and race: results from ACTG A5095/A5097 (abstract no. 132) [online]. Available from URL: http://www.retroconference.org/2004/ [Accessed 2004 Sep 24]
  9. 9.
    Barrett JS, Joshi AS, Chai M, et al. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002; 40: 507–19PubMedGoogle Scholar
  10. 10.
    LaPorte C, Burger D, Gyssens I, et al. Gender differences in nevirapine pharmakokinetics, fact or fiction? [abstract no. 10]. Program and abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy; 2003 Mar 27-29; CannesGoogle Scholar
  11. 11.
    Zhou SJ, Sheiner LB, D’Aquila RTD, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999; 43: 121–8PubMedGoogle Scholar
  12. 12.
    Clark RA, Squires K. Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Rev Anti Infect Ther 2005 Apr; 3(2): 213–27PubMedCrossRefGoogle Scholar
  13. 13.
    Nellen JFJB, Schillevoort I, Wit FWNM, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004; 39: 736–40PubMedCrossRefGoogle Scholar
  14. 14.
    Kosel BW, Beckerman KP, Hayashi S, et al. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17(8): 1195–9PubMedCrossRefGoogle Scholar
  15. 15.
    Acosta EP, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48(2): 430–6PubMedCrossRefGoogle Scholar
  16. 16.
    Lopez-Cortes LF, Ruiz-Valderas R, Pascual R, et al. Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. HIV Clin Trials 2003; 4(3): 227–9PubMedCrossRefGoogle Scholar
  17. 17.
    Stek A, Mirochnick, Capparelli E, et al. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026 [abstract no. Lb0rB08]. XVth International AIDS Conference; 2004 Jul 11-16; BangkokGoogle Scholar
  18. 18.
    Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44: 499–523PubMedCrossRefGoogle Scholar
  19. 19.
    Kashuba A, Nafziger A. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998; 34: 203–18PubMedCrossRefGoogle Scholar
  20. 20.
    Fletcher CV, Hongyu J, Brundage RC, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS clinical trials group study 359. J Infect Dis 2004; 189: 1176–84PubMedCrossRefGoogle Scholar
  21. 21.
    Candaro JA, Morse GD, Baros L, et al. Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. Pharmacotherapy 1993; 13: 369–77Google Scholar
  22. 22.
    Department of Health and Human Services. Antiretroviral treatment adult and adolescent guidelines [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/ [Accessed 2004 Sep 24]Google Scholar
  23. 23.
    Newburger J, Goldzieher JW. Pharmacokinetics of ethinyl estradiol: a current view. Contraception 1985; 32: 33–44PubMedCrossRefGoogle Scholar
  24. 24.
    Frohlich M, Burhenne J, Martin-Facklam M, et al. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004; 57: 244–52PubMedCrossRefGoogle Scholar
  25. 25.
    Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′- azido-3′-deosythymidine and selective interaction of the 5′ triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986; 83: 8333–7PubMedCrossRefGoogle Scholar
  26. 26.
    Hoggard PG, Back DJ. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Curr Opin Infect Dis 2002; 15: 3–8PubMedCrossRefGoogle Scholar
  27. 27.
    Anderson PL, Kakuda TN, Kawle S, et al. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17: 2159–68PubMedCrossRefGoogle Scholar
  28. 28.
    Squires K, Gulick R, Pavia A, et al. Sex differences in the selection of thymidine analog regimen therapy trials (START I and START II) [abstract no. 516]. 7th Conference on Retroviruses and Opportunistic Infections. 2000 Jan 30-Feb 2; San Francisco (CA)Google Scholar
  29. 29.
    Currier J, Spino C, Grimes J. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. J Acquir Immune Defic Syndr 2000; 24: 316–24PubMedGoogle Scholar
  30. 30.
    Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101: 34–40PubMedCrossRefGoogle Scholar
  31. 31.
    Boxwell DE, Styrt BA. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors [abstract no 1284]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999; San Francisco (CA)Google Scholar
  32. 32.
    Mazhude C, Jones S, Taylor C. Ethnic and gender differences in non-nucleoside reverse transcriptase inhibitor (NNRTI) induces rash [abstract no. 526]. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8-11; Buenos AiresGoogle Scholar
  33. 33.
    Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex difference in nevirapine rash. Clin Infect Dis 2001; 32: 124–9PubMedCrossRefGoogle Scholar
  34. 34.
    Wong KH, Chan KC, Lee SS. Sex differences in nevirapine rash. Clin Infect Dis 2001; 33: 2096–8PubMedCrossRefGoogle Scholar
  35. 35.
    Antinori A, Baldini F, Girardi E, et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15: 1579–81PubMedCrossRefGoogle Scholar
  36. 36.
    Bartlett J. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor [abstract no. 19]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb; Chicago (IL)Google Scholar
  37. 37.
    Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor [abstract]. AIDS 2000; 14Suppl. 4: S12Google Scholar
  38. 38.
    Nguyen ML, Nagy GS, Hernandez I, et al. Use of HAART in women: similar response but greater toxicity [abstract no. WePeB5968]. 14th International AIDS Conference; 2002 Jul; BarcelonaGoogle Scholar
  39. 39.
    Jacobson DL, Knox T, Gorbach S, et al. Evolution of fat atrophy (FA) and fat deposition (FD) over 1 year in a cohort of HIV-infected men and women [abstract no. 685-T] [online]. Available from URL: http://www.retroconference.org/2002/ [Accessed 2004 Sep 24]
  40. 40.
    Koko-Ekong S, Azubike U, Edong E, et al. Fat redistribution in HIV Patients on non-protease (PI) Regimens-Study in 6 Centers in Nigeria (abstract no. 684-T) [online]. Available from URL: http://www.retroconference.org/2001/ [Accessed 2004 Sep 24]
  41. 41.
    McDermott AY, Shevitz A, Knox T, et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001; 74: 679–86PubMedGoogle Scholar
  42. 42.
    Galli M, Veglia F, Angarano G, et al. Risk of developing metabolic and morphological alterations under antiretroviral therapy according to drug combinations [abstract no. P61]. Antivir Ther 2000; 5Suppl. 5: 59–60Google Scholar
  43. 43.
    Thiebaut R, Daucourt V, Mercei P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: aquitaine cohort, France, 1999. Clin Infect Dis 2000; 31: 1482–7PubMedCrossRefGoogle Scholar
  44. 44.
    Falutz J, Murrahainen N, Workman C, et al. Gender is associated with increased body size but not fat depletion in patients with HIV-associated adipose redistribution (HARS) [abstract no. WePeB4273]. Programs and abstracts of the 13th International AIDS Conference; 2003; DurbanGoogle Scholar
  45. 45.
    Lichenstien K, Delaney K, Ward D, et al. Clinical factors associated with incidence and prevalence of fat atrophy and accumulation [abstract no. P64). Antivir Ther 2000; 5Suppl. 5: 61–2Google Scholar
  46. 46.
    Martinez E, Mocroft A, Garcia-Viejo M, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: 592–8PubMedCrossRefGoogle Scholar
  47. 47.
    Clark RA, Theall K, Abernathy D, et al. Antiretroviral class effect on risk for selected metabolic complications [abstract no. 931]. Infectious Diseases Society of America Meeting; 2004, Boston (MA)Google Scholar
  48. 48.
    Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001; 15: 725–34PubMedCrossRefGoogle Scholar
  49. 49.
    Almond LM, Boffito M, Hoggard PG, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004; 20: 716–22PubMedCrossRefGoogle Scholar
  50. 50.
    Besch CL. Antiretroviral therapy in drug-naive patients infected with human immunodeficiency virus. Am J Med Sci 2004; 328: 3–9PubMedCrossRefGoogle Scholar
  51. 51.
    Moyle G, Boffito M. Unexpected drug interactions and adverse events with antiretroviral drugs. Lancet 2004; 364: 8–10PubMedCrossRefGoogle Scholar
  52. 52.
    Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269–73PubMedCrossRefGoogle Scholar
  53. 53.
    Arenas-Pinto A, Grant AD, Edwards S, et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 2003; 79: 340–4PubMedCrossRefGoogle Scholar
  54. 54.
    Ibdah JA, Yang Z, Bennett MJ. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab 2000; 71: 182–9PubMedCrossRefGoogle Scholar
  55. 55.
    Hitti J, Frenkel L, Huang S, et al. Toxicity with continuous nevirapine in pregnancy: results from PACTG 1022 (abstract no. 938) [online]. Available from URL: http://www.retroconference.org/2004/ [Accessed 2004 Sep 24]
  56. 56.
    Baylor M, Truffa M, Gibbs N. Hepatic toxicity of antiretrovirals in HIV-infected pregnant women: the FDA’s adverse event reporting system (abstract no. 944) [online]. Available from URL: http://www.retroconference.org/2004/ [Accessed 2004 Sep 24]
  57. 57.
    Currier JS, Yetzer E, Potthoff A, et al. Gender differences in adverse events on ritonavir: an analysis from Abbott 247 [abstract no. 304.7]. 1st National Conference on Women and HIV; 1997 May 7; Pasadena (CA)Google Scholar
  58. 58.
    Gatti G, Di Biagnio A, Beltrame A, et al. Gender as a risk factor for ritonavir intolerance [abstract no. 2210]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA)Google Scholar
  59. 59.
    Gersten M, Chapman S, Farnsworth A, et al. The safety and efficacy of Viracept (nelfinavir mesylate) in female patients who participated in pivotal II/III double blind randomized controlled trials [abstract no. 304.1]. 1st National Conference on Women and HIV; 1997 May 4-7; Pasadena (CA)Google Scholar
  60. 60.
    El-Sadr W, Neaton J, Neuhaus J, et al. Comparison of risk factors for coronary heart disease among men and women enrolled in the SMART Study (CPCRA 065) [abstract 745] [online]. Available from URL: http://www.retroconference.org/2003/ [Accessed 2004 Sep 24]
  61. 61.
    Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84: 1932–7PubMedCrossRefGoogle Scholar
  62. 62.
    Sattler F. Body habitus changes related to lipodystrophy. Clin Infect Dis 2003; 36: S84–90PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.HIV Outpatient ProgramLouisiana State University Health Science CenterNew OrleansUSA

Personalised recommendations